Clinical trials: Controlled Hypertension
Postmenopause, Hypertension
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
- Conditions
- Postmenopause, Hypertension, Pre-Hypertension
- Trial name
- NCT00420342
- Testing
- Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Bayer
Hypertension
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
To compare the safety and efficacy of an aliskiren-based regimen to a lisinopril-based regimen in the treatment of severe hypertension
- Trial name
- NCT00219050
- Testing
- aliskiren
- Where
- 4 sites in Germany, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Novartis
Hypertension
Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study was to characterise the plasma and urine pharmacokinetic profile of Etamicastat (BIA 5-453) and its metabolites after three multiple rising dose regimens of Etamicastat (BIA 5-453).
- Trial name
- NCT03099226
- Testing
- BIA 5-453
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Bial - Portela C S.A.
Essential Hypertension
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
- Trial name
- NCT01289132
- Testing
- Azilsartan, Candesartan cilexetil
- Volunteers
- 926 people
- Sponsor
- Takeda
Hypertension
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan
- Trial name
- NCT01518998
- Where
- South Korea
- Volunteers
- 420 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Resistant Hypertension, Difficult to Control Hypertension
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening.
- Trial name
- DTC/RHS (NCT05247528)
- Testing
- MANP
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- E-Star BioTech, LLC
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Open Angle Glaucoma, Ocular Hypertension
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT03927443
- Testing
- SDP-133, Lumigan
- Sponsor
- Sun Pharmaceutical Industries Limited
Pulmonary Hypertension
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
- Trial name
- NCT00091715
- Testing
- bosentan
- Where
- 34 sites in United States, Australia and 12 more
- Volunteers
- 185 people
- Sponsor
- Actelion
Chronic Kidney Diseases, Hypertension
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled…
- Trial name
- BLOCKCKD (NCT03574363)
- Testing
- KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
- Where
- 2 sites in United States
- Volunteers
- 162 people
- Sponsor
- KBP Biosciences
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Essential Hypertension
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
CS-8635 combines three widely prescribed antihypertensive medications, olmesartan medoxomil(OM), amlodipine (AML), and hydrochlorothiazide (HCTZ), to lower blood pressure.
- Trial name
- NCT01838850
- Where
- 39 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Hypertension
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)
The objective of this study is to evaluate the safety and efficacy of two investigational drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure).
- Trial name
- NCT00274716
- Testing
- MK0736, MK0916
- Volunteers
- 249 people
- Sponsor
- Merck Sharp & Dohme LLC
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00650338
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Santen Inc.
Pre-eclampsia
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine).
- Trial name
- NCT01566630
- Testing
- RLX030
- Where
- 5 sites in United States, Italy
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Hypertension
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
- Trial name
- NCT02178098
- Testing
- ETC-1002
- Where
- 43 sites in United States
- Volunteers
- 143 people
- Sponsor
- Esperion Therapeutics, Inc.
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Open Angle Glaucoma
A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma.
- Trial name
- NCT05160805
- Testing
- ONL1204 Ophthalmic solution (Dose A), ONL1204 Ophthalmic solution (Dose B)
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 25 people
- Sponsor
- ONL Therapeutics
Preeclampsia
KW-3357 Study in Patients With Early Onset Severe Preeclampsia
The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.
- Trial name
- NCT04182373
- Testing
- Antithrombin gamma, physiological saline
- Where
- 63 sites in Japan
- Volunteers
- 181 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypertension, Pulmonary, Ventricular Dysfunction, Left
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
- Trial name
- DILATE (NCT01172756)
- Testing
- Riociguat (BAY63-2521)
- Where
- 7 sites in Austria, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Bayer